Show simple item record

dc.contributor.authorSuryavanshi, Santosh
dc.contributor.authorAnderson, Kody
dc.contributor.authorJadhav, Shweta
dc.contributor.authorLichtarge, Olivier
dc.contributor.authorMcConnell, Bradley K.
dc.description.abstractmAKAP polymorphisms may pre-dispose humans to CVDs by altering cAMP/PKA signaling in the heart. PKA-mAKAP interaction modulators can be developed as therapeutic target to augment current treatment of CVDs. This project was completed with contributions from Alexei Degterev from the Department of Developmental, Molecular and Chemical Biology, School of Medicine, Tufts University, Boston.
dc.titleHuman Muscle-Specific A-Kinase Anchoring Protein (mAKAP) Polymorphisms: Mechanistic Role in Cardiovascular Diseases
dc.description.departmentPharmacological and Pharmaceutical Sciences, Department of

Files in this item


This item appears in the following Collection(s)

  • GRS 2017
    This collection gathers posters, talks, and performances presented at the 2017 Graduate Research and Scholarship Projects Day

Show simple item record